Abivax Announces Trading Resumption on Euronext Paris
Abivax, a pioneering biotechnology company, has successfully announced that its ordinary shares will resume trading on Euronext Paris. This significant development is set to take effect from 3:30 p.m. CEST, following a temporary halt that occurred earlier in the day at 9:00 a.m. CEST. The halt was initiated by the company itself, in light of the ongoing processes surrounding its recent public offering of American Depositary Shares.
Insights into the Offering
The trading halt was a strategic move designed to facilitate the confirmation of allocations to investors involved in the public offering. By pausing trading, Abivax allowed for the necessary arrangements to finalize the pricing of the Offering effectively. As the company continues to advance its innovative therapies, such measures ensure transparency and orderly market operations.
About Abivax and Its Mission
Based in both France and the United States, Abivax is at the forefront of biotechnology, working diligently to develop therapeutics that aim to modulate the immune response recovery for patients suffering from chronic inflammatory diseases. Their lead drug candidate, obefazimod (ABX464), is currently making strides in Phase 3 clinical trials, focusing on treatment for moderately to severely active ulcerative colitis.
Potential of Obefazimod
The journey of Abivax's primary drug candidate highlights a promising avenue for alleviating the burdens of chronic conditions like ulcerative colitis. By leveraging the body’s inherent ability to regulate its immune mechanisms, obefazimod seeks to provide new hope to patients who have faced challenges with existing treatments. This innovative approach is garnering attention within the medical community and offers a refreshing perspective on therapeutic development.
Company Contacts for Investors
For those interested in diving deeper into Abivax's investor relations, please reach out to Patrick Malloy, who serves as the point of contact for inquiries. Patrick is available via email at patrick.malloy@abivax.com or by phone at +1 847 987 4878. His expertise can provide valuable insights regarding the company's trajectory and future initiatives.
Future Outlook
As Abivax moves forward with its initiatives, the biotech landscape is evolving, and the company is poised to make impactful contributions. The successful resumption of trading on Euronext Paris marks a reaffirmation of investor confidence in their mission and enhances opportunities for future fundraising and partnerships. With a commitment to developing life-changing therapies, Abivax is on a path of growth that will likely resonate through the industry in the years to come.
Frequently Asked Questions
What triggered the trading halt of Abivax's shares?
The trading halt was initiated by Abivax to facilitate the public offering of its American Depositary Shares and confirm allocations to investors.
What is the significance of obefazimod in Abivax's pipeline?
Obefazimod is a lead candidate in Phase 3 trials for treating ulcerative colitis, aiming to harness the body's immune response for better outcomes.
Where can I find more information about Abivax's investor relations?
Investors can contact Patrick Malloy at patrick.malloy@abivax.com for inquiries regarding the company.
Which stock exchange lists Abivax shares?
Abivax shares are traded on Euronext Paris under the ticker symbol ABVX.
How does Abivax's approach differ in biotechnology?
Abivax focuses on utilizing the body’s natural mechanisms to modulate the immune response, which is a unique approach in treating chronic inflammatory diseases.
